LIVE Day 2 – 2017 MassBio Annual Meeting March 31, 2017 8:00 AM, Royal Sonesta Boston
Real Time Coverage: Aviva Lev-Ari, PhD, RN
#MassBioAM17 #PATIENTDRIVEN @pharma_BI @AVIVA1950
Day 2
Breakfast
8:00 am – 8:30 am
Pain & Addiction
Trends in Science
8:30 am – 9:30 am
MODERATOR: Vipula Tailor, Medical Immunology
- transdermal transmission
- same platform for DM
- Gender threshold
- Transition from current drugs to new drugs
- lower dose for same efficacy
PANELISTS:
Michael Heffernan, Founder, President & CEO, Collegium Pharmaceutical Inc.
- Drug Extenza – ER, safer opioids
- 2-4 million needs opioids to function in the US
- only 4% of opioids are abused in the US
- Access – Insurance, MedicCare, MedicAid – do not pay for it, doctors need preauthorization
- opioids brings euphoria, mood change
- efficacy – 24 hours, 48 hours, 72 hours
- evolution of thinking
- metabolic aspects, half life
- Best Practice in patient selection for clinical trials – who to select and HOW to screen
- Placibo vs Drug, causing constipation, Impact Group, the data needs be shared
- Opioid abuse in the US, evolution in patient selection if they are not a candidate for opioids
- Comprehensive treatment, pain management is only one component PT, and counseling education, multimodal treatment
- MassHealth, only if you fail opioids one will get Fentanyl
- Decrease Opioids prescribed in MA,
Ajay Yekkirala, CSO and co-Founder, SUBSTITUTE for Michio Painter, Co-Founder & CEO, Blue Therapeutics
- molecule smaller than morphine
- 40% are in chronic pain every day,
- target in nervous system, peripheral pain,
- sensitisation in the CNS will bypass opioids
- Placibo effect
- Class II hard to prescribe
- Reimbursement aspects – IV administration
- 20% of Patients on opioid for 5 days will stay on the drug for 2-3 years
- Gender differences – more Female in Chronic Pain than Males
- Types of Pain: Fibromyalgia vs Post OPS pain
- sharing information of clinical trial on Drug for Pain will be very helpful on Research
John J. Renger, PhD, Head of Clinical Research, Purdue Pharma, L.P.,
- sleep and pain
- change from systemic to local administration for efficacy
- Pain pathways of Pain – four different pathwave each specific for drug development
- Acute pain becomes chronic pain
- Formulation as target
- End point definition – for clinical trial design, time line and expense a challenge for small bio companies
- behavior studies, genetics studies, who respond to what pathway the best
- Genetic profile for efficacy, side effect of responders
- Drug of choice for a type of pain
- electrical stimulation
- genetic studies PRIOR to participation in Clinical Trial
Frank Reynolds, CEO, PixarBio
- local injection opioids
- pre-clinical data
- local toxicity
- morphine strength
- 14 day treatment max – analgesia
- Animal model for Chronic pain is a challenge
- Interrupt in sleep effect on mood, pain signal
- Drug used in Epilepsy and in Parkinson
- Opioids causes respiratory involvement a problem in Children and Elderly
Next Generation Diagnostics
Convergence
8:30 am – 9:30 am
MassCONNECT
Better Business
9:30 am – 10:30 am
CNS
Trends in Science
9:30 am – 10:30 am
MODERATOR:
Kiran Reddy, President & CEO, Praxis Precision Medicines
- AlzheimerDisease and Parkinson
- Now imaging technology used in Parkinson and in AD
- Neuro inflammation in Neurodegenerative diseases: Over or Under activity
- other therapeutics areas
- No biotech in Neuro degeneration from VC point of view – AD and Parkinson, only big Pharma
- CNS was small molecule now moving to gene therapy
- Deep brain stimulation for Parkinson
- Imaging and Diagnostics for CNS disease
- CNS and Psychiatry, ADHD – innovations stopped – How to reinvigorate Psych drug development
PANELISTS:
Stephen Curtis, Director, BD, Emerging Technologies & Innovation, Eli Lilly & Co.
- Eli Lilly is committed to three targets under development: Tau, Neuro inflammation
- Patient selection for Clinical Trials
- Pain is emerging in high interest, one molecule was licensed – now AD and ALS – psychosis
- improve patient quality of life
- Life Sciences Funds in the UK, Eli Lilly invest there, other Big Pharma are also investing in this Fund
- Which pathways and cognition scoring and digital to identify early cognitive decline
- Diagnostics Business Model in Venture Financing – a difficult field
Zaven Kaprielian, Neuroscience Research, Amgen
- Amgen since 1999 partnered with Novartis for Clinical Trial on AD
- Decogenics, app pathway, link between Nate immune and AD
- activation of microglia to accelerate clearance
- genetic targets in ALS
- pathways convergence
- Autism, genetic players
- longevity and CNS disease
- Biomarkers Consortium effort on its way
- TAKE MICROBIOME OF HAPPY PEOPLE AND TRANSFECT INTO DEPRESSED
- Human genetics sequencing families
Penny Hallett, Director, Neuro regeneration Research Institute, McLean Hospital & Asst Prof. HMS
- Parkinson – neuron loss has no recovery of the loss
- Biomarkers
- Parkinson, antibodies, lysosomal targets physiology better understood
- Inflammation and Microbiome changes linked to inflammation and inflammatory response
- Autonomic dysfunction
- chronic systemic infection
- Phenotype mutation in Parkinson
Coffee Break
10:30 am – 10:45 am
Patient Story
10:45 am – 10:50 am
Convergence
Plenary
11:00 am – 12:00 pm
MODERATOR:
Frank David, Managing Director, Pharmagellan
- Why do we care about Convergence
- Digital, Diagnostics, Devices
PANELISTS:
Anne Deconinck, Exec Director, Koch Institute, MIT
- Biological discovery: Engineers and Life Scientist to work on Cancer
- Collaboration, synergies, shared mission
- diversity, different mind sets,
- convergence: Early detection, nanovision for early detection
- devices
- genomics
- following individual cells in the presence of drugs
- T-cells and vaccines as therapeutics
- 50 companies were span off from MIT in last five years, some in Clinical Trials
- Partnerships with Pharma with funds
- One Faculty with a Team for each Labs
- Helping Oncologists making decisions on leukemia using a platform for drug match to patients in Cancer
- ML ids the future for Wellness data to predict disease and improve diagnosis
- New Vaccines,
Ryan Egeland, Sr. Director, BD & Licensing, Medtronic, Surgical Group
- Drug eluting stents
- balloons
- device and drug
- Pacemaker implantable – Digital IT
- $12 Bil Revenues of Medtronic
- Big Pharma $450Billion, devices is a small portion
- Inefficiencies in HealthCare including Dealth by error of treatment or surgical
- 1989, Human Genome Project, George Church foresaw Sequencing the Human Genome for less than $1000
- CHF – expensive disease, time sensitive
- MI – disease stage – idea from Lab to development of device
- Medtronics is Patient centered
- Quality and Health Measure
- Profit and Loss statement: Presence in Device in Pharma – Staff, allocation of staff, IOM – utilize resources in Healthcare
- Peak of Healthcare IT, the trough will come, The Genomics Renaissance will come soon and will touch Devices in 5 years
John Halamka, CIO, BIDMC, solving IT problems
- $2Billion cost of Hospitalization,
- Patient consent for treatment
- Living Health Care Systems, objective and subjective data from Patients, Phenotype and Genotype
- Business Rules applied to EMR, glucometer data,
- Biomarkers used based on Probabilistic model of a disease in a Patient
- Patient interface with a New Application at BIDMC: Who is on the Team for this day, what tests will be done what id the Plan of Care for the day
- Care patient of Geriatric Patient is a Growing Business
- Amazon is hosting in the cloud the Data from BIDMC — the Renaissance in IT is NOW
Rachel Sha, Head, Central Transactions & Digital BD, BD & Licensing, Sanofi
- Drugs: Cheaper, faster – HOW
- Digital development in DM – technology known the variance is life style and exercise
- short term and long term – chasing butterflies
- What to do with DM Data??
- Appetite for Innovations at Sanofi: drug investment
- Midway: speed of uploading data is enabling to innovate
Patient Story
12:00 pm – 12:05 pm
Buffet Lunch
12:05 pm – 12:45 pm
Patient Story
12:45 pm – 12:50 pm
Closing Keynote: What Corporate Executives Can Learn from Donald Trump’s Presidential Victory
Plenary
1:00 pm – 1:30 pm
Dessert Buffet & Networking Reception
1:30 pm – 2:00 pm
Leave a Reply